Citation: Michael Kreuter,David J. Lederer,Maria Molina-Molina,Imre Noth,Claudia Valenzuela,Lutz Frankenstein,Derek Weycker,Mark Atwood,Klaus-Uwe Kirchgaessler,Vincent Cottin, (2019). Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis. CHEST, Volume 156, Issue 4, October 2019, Pages 706-714. https://www.sciencedirect.com/science/article/pii/S0012369219308827 Background Angiotensin peptides have been implicated in idiopathic pulmonary fibrosis (IPF) pathogenesis. Angiotensin modulators are used to treat arterial hypertension, a frequent comorbidity of IPF. […]
Tag: Angiotensin II receptor blocker
Recent Posts
- This PF Awareness Month, Action for Pulmonary Fibrosis is asking everyone to Take Action for PF.
- Association of Angiotensin Modulators With the Course of Idiopathic Pulmonary Fibrosis
- Biomarkers in idiopathic pulmonary fibrosis: Current insight and future direction
- September is Pulmonary Fibrosis Awareness Month
- The similarities and differences between pleuroparenchymal fibroelastosis and idiopathic pulmonary fibrosis
- Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosis
- September is Pulmonary Fibrosis (PF) Awareness Month
- Exercise training in idiopathic pulmonary fibrosis: is it of benefit?
- Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosisand type 2 diabetes mellitus: a national claims‑based cohort analysis
- Plasticity towards Rigidity: A Macrophage Conundrum in
Pulmonary Fibrosis - TIPAL
- Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
- Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
- Mitochondrial Quality Control in COPD and IPF
- Idiopathic Pulmonary Fibrosis (IPF): An Overview
- UK Petition, March 2023
- Pulmonary Fibrosis Research and Education Hub
- Hello world!
Recent Comments
No comments to show.
